Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin 
    		2015 ASH Annual Meeting
    	
    	
    	
    
        Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).
    
    
    
    
       
       
    		Sébastien Maury, MD
		
		
        
		
		
		
		Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1). To see the French language version of this newsreel, please click here.
			
			
     	
    
       
       
    		Simon Rule, MD
		
		
        
		
		
		
		Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).
			
			
     	
    
       
       
    		Andrew J. Davies, MRCP, PhD
		
		
        
		
		
		
		Andrew J. Davies, MRCP, PhD, of the Cancer Research UK Centre, University of Southampton, discusses a study of targeted treatment for diffuse large B-cell lymphoma based on real-time gene-expression profiling (Abstract 812).
			
			
     	
    
       
       
    		Sébastien Maury, MD
		
		
        
		
		
		
		Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses in French this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1).
			
			
     	
    
       
       
    		Alok A. Khorana, MD
		
		
        
		
		
		
		Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).